These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35810360)

  • 1. A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
    Olivas-Mazón R; Bueno D; Sisinni L; Mozo Y; Casado-Abad G; Martínez AP
    Eur J Haematol; 2022 Nov; 109(5):474-482. PubMed ID: 35810360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
    Galán V; Beléndez C; Echecopar C; Estival P; Sissini L; Olivas R; Bueno D; Molina B; Fuentes C; Regueiro A; Benítez I; Plaza M; Margarit A; Rifón J; Pascual A; Palomo P; Urtasun A; Fuster JL; Díaz de Heredia C; Fernández Navarro JM; González-Vicent M; Ruz B; Pérez-Martínez A
    Transplant Cell Ther; 2023 Nov; 29(11):702.e1-702.e11. PubMed ID: 37595686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center.
    Uzay A; Gündoğdu Y; Koşan B; Yetiş T; Kartı SS
    Cancer Med; 2024 May; 13(10):e7292. PubMed ID: 38752476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treosulfan Versus Busulfan-based Conditioning in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis.
    Wu W; Xue N; Yang H; Gao P; Guo J; Han D
    J Pediatr Hematol Oncol; 2023 Oct; 45(7):370-376. PubMed ID: 37526377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
    Huttunen P; Taskinen M; Vettenranta K
    Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulfan-Based and Treosulfan-Based Myeloablative Conditioning for Allogeneic Transplantation in Children with Thalassemia Major: a Single-Center Experience From Southern Turkey.
    Aygüneş U; Karagun BS; Ay Tuncel D; Sasmaz HI; Antmen B
    Exp Clin Transplant; 2023 Nov; 21(11):883-892. PubMed ID: 38140932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Treosulfan- or Busulfan-Based Conditioning in Pediatric Patients with Acute Leukemia or Myelodysplastic Syndrome: Results of an Associazione Italiana Ematologia Oncologia Pediatrica Retrospective Study.
    Saglio F; Pagliara D; Zecca M; Balduzzi A; Cattoni A; Prete A; Tambaro FP; Faraci M; Calore E; Locatelli F; Fagioli F;
    Transplant Cell Ther; 2024 Apr; 30(4):433.e1-433.e10. PubMed ID: 38176654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool.
    van der Stoep MYEC; Berghuis D; Bredius RGM; Buddingh EP; Mohseny AB; Smiers FJW; Guchelaar HJ; Lankester AC; Zwaveling J
    Sci Rep; 2021 Sep; 11(1):19084. PubMed ID: 34580398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in high-risk patients with primary immune deficiencies.
    Haskoloğlu Ş; Köstel Bal S; İslamoğlu C; Altun D; Kendirli T; Doğu EF; İkincioğulları A
    Pediatr Transplant; 2018 Nov; 22(7):e13266. PubMed ID: 29992714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
    Morillo-Gutierrez B; Beier R; Rao K; Burroughs L; Schulz A; Ewins AM; Gibson B; Sedlacek P; Krol L; Strahm B; Zaidman I; Kalwak K; Talano JA; Woolfrey A; Fraser C; Meyts I; Müller I; Wachowiak J; Bernardo ME; Veys P; Sykora KW; Gennery AR; Slatter M
    Blood; 2016 Jul; 128(3):440-8. PubMed ID: 27216217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
    Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
    Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
    Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
    Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
    Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
    Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
    Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
    Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study.
    van der Stoep MYEC; Bertaina A; Moes DJAR; Algeri M; Bredius RGM; Smiers FJW; Berghuis D; Buddingh EP; Mohseny AB; Guchelaar HJ; Locatelli F; Zwaveling J; Lankester AC
    Transplant Cell Ther; 2022 Feb; 28(2):99.e1-99.e7. PubMed ID: 34607071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
    Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
    Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.
    Solans BP; Chiesa R; Doncheva B; Prunty H; Veys P; Trocóniz IF; Standing JF
    Br J Clin Pharmacol; 2020 Aug; 86(8):1537-1549. PubMed ID: 32077123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial.
    Sykora KW; Beier R; Schulz A; Cesaro S; Greil J; Gozdzik J; Sedlacek P; Bader P; Schulte J; Zecca M; Locatelli F; Gruhn B; Reinhardt D; Styczynski J; Piras S; Fagioli F; Bonanomi S; Caniglia M; Li X; Baumgart J; Kehne J; Mielcarek-Siedziuk M; Kalwak K
    Bone Marrow Transplant; 2024 Jan; 59(1):107-116. PubMed ID: 37925531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.